Get the Stockscreener App
5.70
8.78%
+0.46
ZyVersa Therapeutics Inc stock is currently priced at $5.70, with a 24-hour trading volume of 67,448.
It has seen a +8.78% increased in the last 24 hours and a +681.89% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $5.43 pivot point. If it approaches the $5.71 resistance level, significant changes may occur.
Previous Close:
$5.24
Open:
$5.2
24h Volume:
67,448
Market Cap:
$3.98M
Revenue:
-
Net Income/Loss:
$-98.30M
P/E Ratio:
-0.7906
EPS:
-7.2097
Net Cash Flow:
$-8.72M
1W Performance:
+838.27%
1M Performance:
+681.89%
6M Performance:
+5,795%
1Y Performance:
+1,040%
1D Range:
$5.15
$5.71
52W Range:
$0.0541
$6.70
ZyVersa Therapeutics Inc Stock (ZVSA) Company Profile
Name
ZyVersa Therapeutics Inc
Sector
Industry
Phone
754 231 1688
Address
2200 N. Commerce Parkway, Suite 208, Weston
ZyVersa Therapeutics Inc Stock (ZVSA) Latest News
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
GlobeNewswire Inc.
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
GlobeNewswire Inc.
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire Inc.
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
GlobeNewswire Inc.
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
GlobeNewswire Inc.
ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity
GlobeNewswire Inc.
ZyVersa Therapeutics Inc Stock (ZVSA) Financials Data
ZyVersa Therapeutics Inc (ZVSA) Net Income 2024
ZVSA net income (TTM) was -$98.30 million for the quarter ending December 31, 2023, a -599.75% decrease year-over-year.
ZyVersa Therapeutics Inc (ZVSA) Cash Flow 2024
ZVSA recorded a free cash flow (TTM) of -$8.72 million for the quarter ending December 31, 2023, a -483.49% decrease year-over-year.
ZyVersa Therapeutics Inc (ZVSA) Earnings per Share 2024
ZVSA earnings per share (TTM) was -$194.32 for the quarter ending December 31, 2023, a -148.47% decline year-over-year.
About ZyVersa Therapeutics Inc
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
0.49%
4.00%
Cap:
|
Volume (24h):